Logo image of MORF

MORPHIC HOLDING INC (MORF) Stock Fundamental Analysis

NASDAQ:MORF - US61775R1059 - Common Stock

56.99 USD
+0.02 (+0.04%)
Last: 8/15/2024, 8:13:37 PM
56.99 USD
0 (0%)
After Hours: 8/15/2024, 8:13:37 PM
Fundamental Rating

3

Overall MORF gets a fundamental rating of 3 out of 10. We evaluated MORF against 549 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MORF as it has an excellent financial health rating, but there are worries on the profitability. MORF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MORF had negative earnings in the past year.
MORF had a negative operating cash flow in the past year.
In the past 5 years MORF always reported negative net income.
MORF had a negative operating cash flow in each of the past 5 years.
MORF Yearly Net Income VS EBIT VS OCF VS FCFMORF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M -150M

1.2 Ratios

MORF has a better Return On Assets (-27.83%) than 71.70% of its industry peers.
Looking at the Return On Equity, with a value of -29.08%, MORF belongs to the top of the industry, outperforming 81.02% of the companies in the same industry.
Industry RankSector Rank
ROA -27.83%
ROE -29.08%
ROIC N/A
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
MORF Yearly ROA, ROE, ROICMORF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

MORF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MORF Yearly Profit, Operating, Gross MarginsMORF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

MORF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MORF has been increased compared to 1 year ago.
MORF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MORF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MORF Yearly Shares OutstandingMORF Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MORF Yearly Total Debt VS Total AssetsMORF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 60.78 indicates that MORF is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 60.78, MORF belongs to the top of the industry, outperforming 98.42% of the companies in the same industry.
MORF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 60.78
ROIC/WACCN/A
WACC10.56%
MORF Yearly LT Debt VS Equity VS FCFMORF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 24.13 indicates that MORF has no problem at all paying its short term obligations.
With an excellent Current ratio value of 24.13, MORF belongs to the best of the industry, outperforming 95.43% of the companies in the same industry.
MORF has a Quick Ratio of 24.13. This indicates that MORF is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 24.13, MORF belongs to the best of the industry, outperforming 95.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.13
Quick Ratio 24.13
MORF Yearly Current Assets VS Current LiabilitesMORF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MORF have decreased strongly by -15.74% in the last year.
The Revenue for MORF has decreased by -100.00% in the past year. This is quite bad
Measured over the past years, MORF shows a very negative growth in Revenue. The Revenue has been decreasing by -31.12% on average per year.
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MORF will show a small growth in Earnings Per Share. The EPS will grow by 0.11% on average per year.
Based on estimates for the next years, MORF will show a very strong growth in Revenue. The Revenue will grow by 213.82% on average per year.
EPS Next Y-16.05%
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
EPS Next 5Y0.11%
Revenue Next Year-50.42%
Revenue Next 2Y-24.72%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MORF Yearly Revenue VS EstimatesMORF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
MORF Yearly EPS VS EstimatesMORF Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MORF. In the last year negative earnings were reported.
Also next year MORF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MORF Price Earnings VS Forward Price EarningsMORF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MORF Per share dataMORF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

MORF's earnings are expected to decrease with -8.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MORF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MORPHIC HOLDING INC

NASDAQ:MORF (8/15/2024, 8:13:37 PM)

After market: 56.99 0 (0%)

56.99

+0.02 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-25 2024-07-25/bmo
Earnings (Next)11-01 2024-11-01/bmo
Inst Owners1.36%
Inst Owner Change0%
Ins Owners15.53%
Ins Owner Change0%
Market Cap2.85B
Analysts73.33
Price Target59.6 (4.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.15%
Min EPS beat(2)-15.97%
Max EPS beat(2)3.68%
EPS beat(4)2
Avg EPS beat(4)0.47%
Min EPS beat(4)-15.97%
Max EPS beat(4)25.02%
EPS beat(8)4
Avg EPS beat(8)3.24%
EPS beat(12)6
Avg EPS beat(12)16.34%
EPS beat(16)7
Avg EPS beat(16)16.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.22%
PT rev (3m)0.22%
EPS NQ rev (1m)1.34%
EPS NQ rev (3m)-2.79%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-2.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-12.5%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.62
P/tB 4.62
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-2.75
FCFYN/A
OCF(TTM)-2.72
OCFYN/A
SpS0
BVpS12.35
TBVpS12.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.83%
ROE -29.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.83%
ROA(5y)-19.11%
ROE(3y)-22.37%
ROE(5y)-25.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 120.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.13
Quick Ratio 24.13
Altman-Z 60.78
F-Score2
WACC10.56%
ROIC/WACCN/A
Cap/Depr(3y)83.14%
Cap/Depr(5y)112.12%
Cap/Sales(3y)81.29%
Cap/Sales(5y)51.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-16.05%
EPS Next 2Y-11.1%
EPS Next 3Y-8.78%
EPS Next 5Y0.11%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-77.37%
Revenue growth 5Y-31.12%
Sales Q2Q%N/A
Revenue Next Year-50.42%
Revenue Next 2Y-24.72%
Revenue Next 3Y-7.43%
Revenue Next 5Y213.82%
EBIT growth 1Y-49.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.66%
EBIT Next 3Y-21.14%
EBIT Next 5YN/A
FCF growth 1Y-41.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.79%
OCF growth 3YN/A
OCF growth 5YN/A